Murray JL - Search Results

1

Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast.

Kuerer HM, Peoples GE, Sahin AA, Murray JL, Singletary SE, Castilleja A, Hunt KK, Gershenson DM, Ioannides CG. Kuerer HM, et al. Among authors: murray jl. J Interferon Cytokine Res. 2002 May;22(5):583-92. doi: 10.1089/10799900252982061. J Interferon Cytokine Res. 2002. PMID: 12060497

2

Clinical studies of vaccines targeting breast cancer.

Ko BK, Kawano K, Murray JL, Disis ML, Efferson CL, Kuerer HM, Peoples GE, Ioannides CG. Ko BK, et al. Among authors: murray jl. Clin Cancer Res. 2003 Aug 15;9(9):3222-34. Clin Cancer Res. 2003. PMID: 12960107 Review.

3

Growth and antigen recognition of tumor-infiltrating lymphocytes from human breast cancer.

Hudson JM, Castilleja A, Murray JL, Honda T, Kudelka A, Singletary E, Wharton JT, Ioannides CG. Hudson JM, et al. Among authors: murray jl. J Interferon Cytokine Res. 1998 Jul;18(7):529-36. doi: 10.1089/jir.1998.18.529. J Interferon Cytokine Res. 1998. PMID: 9712369

4

Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients.

Tuttle TM, Anderson BW, Thompson WE, Lee JE, Sahin A, Smith TL, Grabstein KH, Wharton JT, Ioannides CG, Murray JL. Tuttle TM, et al. Among authors: murray jl. Clin Cancer Res. 1998 Aug;4(8):2015-24. Clin Cancer Res. 1998. PMID: 9717833

5

Secretion of CXC chemokine IP-10 by peripheral blood mononuclear cells from healthy donors and breast cancer patients stimulated with HER-2 peptides.

Lee TV, Kim DK, Peoples GE, Castilleja A, Murray JL, Gershenson DM, Ioannides CG. Lee TV, et al. Among authors: murray jl. J Interferon Cytokine Res. 2000 Apr;20(4):391-401. doi: 10.1089/107999000312333. J Interferon Cytokine Res. 2000. PMID: 10805374

6

Clinical trials of HER-2/neu-specific vaccines.

Murray JL, Przepiorka D, Ioannides CG. Murray JL, et al. Semin Oncol. 2000 Dec;27(6 Suppl 11):71-5; discussion 92-100. Semin Oncol. 2000. PMID: 11236031 Review.

7

Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.

Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, Hortobagyi GN, Kudelka AP, Grabstein KH, Cheever MA, Ioannides CG. Murray JL, et al. Clin Cancer Res. 2002 Nov;8(11):3407-18. Clin Cancer Res. 2002. PMID: 12429628

8

Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes.

Ko BK, Efferson CL, Kawano K, Kuerer HM, Sahin A, Murray JL, Ioannides CG. Ko BK, et al. Among authors: murray jl. Int J Oncol. 2004 Jun;24(6):1413-8. Int J Oncol. 2004. PMID: 15138582

9

Sensitivity of undifferentiated, high-TCR density CD8+ cells to methylene groups appended to tumor antigen determines their differentiation or death.

Kawano K, Efferson CL, Peoples GE, Carter D, Tsuda N, Murray JL, Ioannides CG. Kawano K, et al. Among authors: murray jl. Cancer Res. 2005 Apr 1;65(7):2930-7. doi: 10.1158/0008-5472.CAN-04-2232. Cancer Res. 2005. PMID: 15805296

10

CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37).

Mittendorf EA, Holmes JP, Murray JL, von Hofe E, Peoples GE. Mittendorf EA, et al. Among authors: murray jl. Expert Opin Biol Ther. 2009 Jan;9(1):71-8. doi: 10.1517/14712590802614538. Expert Opin Biol Ther. 2009. PMID: 19063694 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

272 results

Search Page

Filters